PDCD1 and pneumonitis: A meta-analysis showed pneumonitis and dyspnea are more likely to occur in mRCC, while arthralgia, hypothyroidism, rash, pruritus, and diarrhea are more likely to occur in melanoma when treated with anti-PD-1 inhibitors [57].